^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | obrixtamig (BI 764532) (CD3 agonist, DLL3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers
Published date:
10/03/2023
Excerpt:
Oxford BioTherapeutics...announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BI 764532 for the treatment of extensive stage small cell lung cancer (ES-SCLC) whose disease has progressed following at least two prior lines of treatment including platinum-based chemotherapy, and of advanced or metastatic extrapulmonary neuroendocrine carcinomas (epNEC) whose disease has progressed following at least one prior line of treatment including platinum-based chemotherapy.
